Our multidisciplinary team approach to multiple myeloma and related diseases draws on the expertise of hematologic oncologists, radiation oncologists, radiologists, pathologists, and bone marrow transplant and pain specialists, among others, who collaborate closely on each patient’s care. We have decades of experience in treating these conditions, and were among the first to recognize the therapeutic value of drugs such as thalidomide and proteasome inhibitors, as well as the predictive power of a serum-free light chain assay for assessing relapse risk. We continue our successful program in stem cell transplantation as we simultaneously test new treatments, diagnostic tools, and DNA testing approaches for projecting individual cancer response.